Login

EUROPEAN RADIATION RESEARCH 2012

15–19 Oct 2012
Vietri sul Mare
Europe/Rome timezone

Support

Session

Modulation of Radiosensitivity

MRS
18 Oct 2012, 17:15
Vietri sul Mare

Vietri sul Mare

Presentation materials

There are no materials yet.

  1. 25. Hypoxia gene expression classifier predicts benefit from radiosensitizers
    Jan Alsner (Aarhus University Hospital)
    18/10/2012, 17:15
    Modulation of Radiosensitivity
    oral (invited speaker)
    Hypoxic tumours are associated with increased resistance to radiotherapy. In head and neck squamous cell carcinomas (HNSCC), this resistance can be counteracted via addition of hypoxic modification to the radiotherapy. Tumours are heterogeneous with respect to the degree and extend of hypoxia, and several methods have been developed to detect relevant tumour hypoxia. These include direct...
    Go to contribution page
  2. 20. Immunological aspects of the modulation of the radiosensitivity by hyperthermia
    Prof. Udo Gaipl (Department of Radiation Oncology, University Hospital Erlangen)
    18/10/2012, 17:45
    Modulation of Radiosensitivity
    oral (invited speaker)
    Hyperthermia (HT) has been shown in various cell culture, preclinical animal and clinical models to be a very potent radio- and chemosensitizer. Recent research suggests that local heating (41-43°C for 1 hour) of the tumour may lead to abscopal, systemic and immune stimulatory effects, since cancer cells can be rendered visible to the immune system by standard therapies either alone or in...
    Go to contribution page
  3. 55. The role of TGFbeta3 and induced nitric oxide activity in connection with induced resistance against low dose hyper-radiosensitivity
    Dr Nina F. Jeppesen Edin (University of Oslo)
    18/10/2012, 18:15
    Modulation of Radiosensitivity
    oral (20 minutes)
    We have previously found that protracting a priming dose of 0.3 Gy over 1 hour resulted in permanent elimination of low dose hyper radio-sensitivity (HRS) instead of the transient elimination by an acute priming with the same dose. The cells exposed to the low dose-rate priming secreted a factor into the medium, which removed HRS transiently in recipient cells. The factor could also be induced...
    Go to contribution page
  4. 133. Association between XRCC1 polymorphisms and acute side effects induced by radiotherapy in breast cancer patients
    Dr Clarice Patrono (ENEA C.R. CASACCIA, Rome, Italy)
    18/10/2012, 18:35
    Modulation of Radiosensitivity
    oral (20 minutes)
    Clarice Patrono1, Laura Verna2, Silvia Sterpone3, Valentina Palma1, Renata Cozzi3, Antonella Testa1 1ENEA Casaccia, Rome, Italy; 2S. Pietro Hospital, Radiotherapy Unit, Rome Italy; 3Department of Biology, “Roma Tre” University, Rome, Italy Therapeutic exposure to ionizing radiation can induce normal tissue side effects which consistently differ among individuals suggesting a possible...
    Go to contribution page
  5. 211. Telomere profiling : toward glioblastoma personalized medicine
    Mr Sylvain FERRANDON (EMR3738-Cellular and Molecular Radiobiology Laboratory)
    18/10/2012, 18:55
    Modulation of Radiosensitivity
    oral (20 minutes)
    Despite a standard of care combining surgery, radiotherapy (RT) and Temozolomide chemotherapy, average. Glioblastoma patient survival is still less than one year. However, recent advances in molecular signalization profiling in glioblastoma have provided new targets for personalized medicine development and new irradiation techniques, such as carbon ion Hadrontherapy, are now available. The...
    Go to contribution page
Building timetable...